AstraZeneca may seek to increase its stake in a diabetes joint venture with Bristol-Myers Squibb, following a decision by the U.S. firm to exit diabetes drug research, according to Citi. Bristol said on Thursday it would no longer conduct research to discover new drugs for diabetes, hepatitis C and neuroscience, but will increase spending on medicines that harness the immune system to fight cancer. That refocusing suggests Bristol could seek to sell its share in the non-U.S. part of the diabetes joint venture to its partner AstraZeneca, Citi analyst Andrew Baum said in a note on Friday.
Help employers find you! Check out all the jobs and post your resume.
